Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. The company was founded in 1952 and is headquartered in Parsippany, NJ.
Clinical Trials
0
0 active
Approvals
51
Total approvals
Agencies
2
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No trial data available
- Australia is vaccinating 5,000 little penguins on Phillip Island against H5N1 using the Zoetis H5N2-subtype killed-virus vaccine, not an mRNA product. - Veterinary and agriculture officials confirmed the inactivated vaccine contains no live virus and cannot cause disease or replicate in recipients. - The unprecedented rollout follows Australia's first H5N1 detection in June 2026 and 484 confirmed H5 wildlife events as of September 4. - Vaccine scientists say no scientific data supports claims that mRNA vaccines are inherently harmful or capable of altering a recipient's genome.
- TD Cowen analyst Steve Scala initiated coverage of AbbVie with a Buy rating and a price target of $280.00. - Scala is a 4-star analyst with an average return of 10.5% and a 62.87% success rate, covering the healthcare sector. - Bank of America Securities' Jason Gerberry also issued a Buy on AbbVie, while Bernstein maintained a Hold rating on July 22. - AbbVie reported quarterly revenue of $15 billion and net profit of $699 million for the quarter ending March 31.
- Two U.S. biotech companies, Akston Biosciences and OKAVA Pharmaceuticals, have launched early-stage clinical trials testing GLP-1 weight-loss therapies for overweight and obese cats. - Approximately 61% of cats and 59% of dogs evaluated by U.S. veterinary professionals in 2022 were classified as overweight or obese, according to the Association for Pet Obesity Prevention. - Morgan Stanley analyst Simeon Gutman describes the trend as "an expansion from premiumization into medicalization," with U.S. pet spending projected to grow from $196 billion in 2025 to over $240 billion by 2030. - Top-line results from both feline GLP-1 clinical trials are expected later this year, though affordability concerns may constrain widespread adoption in veterinary medicine.
- Porcine Group A rotavirus (RVA) causes watery diarrhea in piglets aged 1–8 weeks, with incidence reaching 80–100% and mortality of 10–50%, imposing substantial economic losses on the global swine industry. - Existing vaccines rely on genotype-matched VP7/VP4 antigens, but continuous genetic reassortment and point mutations drive antigenic drift and shift, sharply reducing cross-protection against emerging G/P strains. - Adjuvant strategies—including TLR agonists, saponins, and nanoparticle carriers—are emerging as the most feasible route to broaden protection and induce intestinal mucosal sIgA without altering antigen composition. - Porcine RVA poses a zoonotic risk, with human-swine reassortant strains and high seroprevalence among pig farm workers underscoring the public health value of broad-spectrum vaccines.
- Eli Lilly reported Q1 revenues of $19.8 billion, up 55.5% year-on-year, beating analyst estimates by 13.7% and posting the fastest revenue growth among branded pharma peers. - Merck delivered revenues of $16.29 billion, a 4.9% increase year-on-year, exceeding analyst expectations by 3% with a beat on EPS estimates. - Supernus Pharmaceuticals posted revenues of $207.7 million, up 38.6% year-on-year, driven by a 56% increase in combined growth product revenues, though EPS estimates were significantly missed. - The broader branded pharmaceuticals sector saw aggregate revenues beat consensus estimates by 3.6%, with tailwinds from precision medicine and AI adoption offset by pricing pressures and patent cliffs.
- Moderna announced organizational changes including expanding President Stephen Hoge's role and appointing Ester Banque as Chief Commercial Officer to prepare for multiple product launches. - The company anticipates up to three new product launches in 2027 and 2028, including a flu plus COVID combination vaccine, seasonal flu vaccine, and norovirus vaccine. - Pivotal data readouts expected this year for intismeran (individualized neoantigen therapy) and propionic acidemia therapeutic could support first oncology and rare disease launches. - The FDA is set to review Moderna's flu vaccine mFlusiva with an advisory committee meeting on June 18 and a regulatory decision expected by August 5.
- Zoetis has received regulatory approval for Lenivia, a new monoclonal antibody therapy for canine osteoarthritis, expanding its Companion Animal portfolio. - The approval offers veterinarians an additional osteoarthritis treatment option alongside the company's existing Librela product. - The launch comes amid ongoing securities class actions alleging misleading statements about Companion Animal growth and safety concerns related to Librela. - Investors are watching closely for adoption rates in the UK market and how Zoetis positions Lenivia relative to its other pain therapies.
- The global veterinary drugs market was valued at $53.1 billion in 2024 and is projected to reach $121.2 billion by 2034, growing at a CAGR of 8.6%. - North America led the market with a 41.1% revenue share in 2023, while Asia-Pacific is expected to register the highest CAGR during the forecast period. - Pharmaceuticals dominated the product segment at 47.6% share, with injectables capturing 44.3% of the route of administration category. - The industry is shifting toward biologics including monoclonal antibodies and engineered vaccines, alongside increasing integration of AI and digital health platforms.
- The UK's Veterinary Medicines Directorate approved Zoetis' Lenivia (izenivetmab injection) on May 29, making it the first long-acting anti-NGF monoclonal antibody for canine OA with once-every-three-months dosing. - Lenivia targets nerve growth factor (NGF), a key mediator of pain signaling and inflammation in osteoarthritic joints, providing three months of pain alleviation from a single injection. - Field studies demonstrated improved mobility and reduced pain from the first injection, with early response potentially improving owner compliance and long-term outcomes. - The approval expands the UK veterinary toolkit beyond NSAIDs and monthly anti-NGF options like Librela, offering clinicians a new option for individualized chronic OA pain management.
- The U.S. Food and Drug Administration approved Tessie (tasipimidine) oral solution on May 6, 2026, marking the first veterinary approval for this Orion proprietary molecule in the United States. - Tasipimidine acts in the central nervous system by blocking the startle reflex to counteract arousal, providing a novel mechanism for treating noise aversion and separation anxiety in dogs. - Zoetis will exclusively market and sell Tessie in the United States starting mid-2027, expanding their behavioral product portfolio alongside existing treatments Sileo and Bonqat. - The approval represents a significant advancement in veterinary behavioral medicine, addressing clearly identified clinical needs in companion animal care.
